February 11, 2022 -- IsoPlexis has published a study in Cell, led by the Institute for Systems Biology and the Seattle COVID consortium, in which researchers used IsoPlexis' single-cell functional proteomics platform to identify factors that may predict sustained disease after COVID-19 infection, also known as post-acute sequelae of COVID-19 (PASC) or long COVID.
In the paper, researchers correlated patient symptoms with in-depth profiling of blood cells and plasma components throughout COVID-19 infection to identify factors associated with the development of PASC. PASC, the technical long COVID, is a range of new, returning, or ongoing health problems people can experience four or more weeks following infection. The authors followed 309 patients from initial clinical diagnosis to early-stage recovery from acute disease, spanning up to two to three months post-diagnosis, as well as 457 control patients.
Using IsoPlexis' single-cell functional proteomics platform, the researchers were able to identify correlations between the enhanced presence of certain polyfunctional immune cell types and the presentation of inflammation associated with PASC:
IsoPlexis' single-cell functional proteomics provided a unique assessment to dissect the functional impacts of different cell types across multiple time points and the interplay between innate and adaptive immune responses that contributed to effector functions or inflammation in PASC.
This study follows a previously published Immunity paper, where IsoPlexis' platform identified mechanisms of inflammation in moderate to severe cases of COVID-19.